David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Oct

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

Classifying Pancreatic Cysts Using AI Models

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

Physician-Complementing Artificial Intelligence in Oncology